Showing results (31-40 of 83) with videos related to
Sort By:
Pageof 9
Molecular Neurobiology|February 16, 2026
BDNF and GDNF in Parkinson's Disease: Associations with Clinical Features, Disease Course, and Progression-A Systematic ReviewJulia Węgrzynek-Gallina, Aleksandra Buczek, Jakub Malkiewicz, et al.Postepy Psychiatrii Neurologii|December 16, 2024
Is this a stroke? The profile of patients with suspected acute cerebrovascular accident transferred by ambulance to the Neurology Emergency DepartmentJakub Malkiewicz, Michał Borończyk, Julia Węgrzynek-Gallina, et al.Journal of Clinical Medicine|June 12, 2026
Smoking, Comorbidities, and Low Sun Exposure Are Associated with Clinical and Radiological Outcomes in Patients with Multiple Sclerosis-A Four-Year Observational Cohort StudyWeronika Galus, Mateusz Winder, Aleksander Jerzy Owczarek, et al.Medicina (Kaunas, Lithuania)|September 27, 2025
Real-World Data of First 12-Months of Ofatumumab Treatment in Multiple Sclerosis Patients-A Multicenter Experience from Tertiary Referral CentersWeronika Galus, Aleksandra Kaczmarczyk, Anna Walawska-Hrycek, et al.Medicina (Kaunas, Lithuania)|September 28, 2021
The Influence of Serum Uric Acid Level on Non-Motor Symptoms Occurrence and Severity in Patients with Idiopathic Parkinson's Disease and Atypical Parkinsonisms-A Systematic ReviewAnna Grażyńska, Klaudia Adamczewska, Sofija Antoniuk, et al.Postepy Psychiatrii Neurologii|January 5, 2026
Late-onset myelin oligodendrocyte glycoprotein antibody-associated disease: an underrecognized entity in clinical practice; what does its course in later life teach us? A case report and narrative reviewMichalina Rzepka, Mateusz Toś, Piotr T Oleksy, et al.Nutrients|July 30, 2025
Does Vitamin D Supplementation Slow Brain Volume Loss in Multiple Sclerosis? A 4-Year Observational StudyWeronika Galus, Mateusz Winder, Aleksander J Owczarek, et al.Journal of Alzheimer'S Disease : JAD|January 13, 2024
Quantitative EEG Spectral and Connectivity Analysis for Cognitive Decline in Amnestic Mild Cognitive ImpairmentKatarzyna Zawiślak-Fornagiel, Daniel Ledwoń, Monika Bugdol, et al.Medicina (Kaunas, Lithuania)|January 25, 2025
Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson's Disease-Patient PerspectiveJulia Węgrzynek-Gallina, Tomasz Chmiela, Michał Borończyk, et al.Life (Basel, Switzerland)|December 30, 2025
The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical TrialsJoanna Pilśniak, Julia Węgrzynek-Gallina, Błażej Bednarczyk, et al.Pageof 9